Takeyama Yasuaki, Kanegae Kazuko, Inomata Shinjiro, Takata Kazuhide, Tanaka Takashi, Ueda Shu-Ichi, Yokoyama Keiji, Morihara Daisuke, Nishizawa Shinya, Anan Akira, Irie Makoto, Iwata Kaoru, Shakado Satoshi, Sohda Tetsuro, Sakisaka Shotaro
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
Med Mol Morphol. 2010 Sep;43(3):134-8. doi: 10.1007/s00795-009-0480-9. Epub 2010 Sep 21.
To examine the mRNA expression of hepatobiliary transporters in primary biliary cirrhosis (PBC) patients and to compare bile acid absorption, synthesis, and efflux in patients with non-end-stage and end-stage PBC, we obtained liver samples from PBC patients by percutaneous needle biopsy. End-stage PBC was defined as follows: histological stage IV; cirrhosis; serum total bilirubin, ≥4.0 mg/dl; and Child-Pugh Class C. The mRNA expression levels of sodium taurocholate cotransporting polypeptide (NTCP), bile salt export pump (BSEP), and hepatic cholesterol 7α-hydroxylase (CYP7A1) were significantly higher in the PBC patients than in the controls (P < 0.01). The mRNA levels of NTCP and BSEP were significantly higher in the end-stage PBC patients than in the controls (P < 0.01). However, hepatic CYP7A1 mRNA expression decreased significantly (by 70%) in the patients with end-stage PBC as compared to the controls and the patients with non-end-stage PBC (P < 0.01). The hepatic expression of transporters mediating bile acid influx and efflux showed sustained elevation, whereas that of the rate-limiting enzyme for bile acid biosynthesis was attenuated in the end-stage PBC patients. Thus, mechanisms may be present preventing the accumulation of toxic bile acids in the hepatocytes of end-stage PBC patients.
为了检测原发性胆汁性肝硬化(PBC)患者肝胆转运体的mRNA表达,并比较非终末期和终末期PBC患者的胆汁酸吸收、合成及流出情况,我们通过经皮肝穿刺活检获取了PBC患者的肝脏样本。终末期PBC的定义如下:组织学分期为IV期;肝硬化;血清总胆红素≥4.0mg/dl;Child-Pugh分级为C级。PBC患者中牛磺胆酸钠共转运多肽(NTCP)、胆盐输出泵(BSEP)和肝脏胆固醇7α-羟化酶(CYP7A1)的mRNA表达水平显著高于对照组(P<0.01)。终末期PBC患者中NTCP和BSEP的mRNA水平显著高于对照组(P<0.01)。然而,与对照组和非终末期PBC患者相比,终末期PBC患者的肝脏CYP7A1 mRNA表达显著降低(降低70%)(P<0.01)。在终末期PBC患者中,介导胆汁酸流入和流出的转运体的肝脏表达持续升高,而胆汁酸生物合成限速酶的表达则减弱。因此,可能存在一些机制来防止终末期PBC患者肝细胞中有毒胆汁酸的积累。